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Introduction: Transient psychotic symptoms in patients with borderline personality disorder 
seem to be similar to those in patients with psychotic disorders. Especially in the field of 
early detection of psychosis, this might lead to individuals with borderline personality disorder 
being wrongly classified as subjects at risk for developing a manifest psychosis. The aim of 
the present study was to investigate the occurrence of borderline symptoms in a sample of 
subjects at risk for psychosis as well as possible effects on the transition rate. 
Methods: Seventy help-seeking individuals of an early psychosis recognition center were 
additionally examined for borderline symptoms by the borderline symptom checklist. 
Results: We found a significant correlation between borderline symptomatology and 
positive symptoms assessed by the structured interview for prodromal symptoms. There 
were no associations between basic symptoms for psychosis and borderline symptoms. 
In addition, there was no influence of borderline symptomatology on the rate of transition 
into a manifest schizophrenic disease. 
Summary: In conclusion, borderline personality disorder should not be an exclusion 
criterion for the screening for psychosis or for an early intervention treatment. On the other 
hand, not every patient with borderline personality disorder, (especially those not suffering 
from hallucinations, unusual thought content, or persecutory ideas) should automatically 
be screened for the risk of developing a psychotic disorder.
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INTRODUCTION
Early views of borderline personality disorder (BPD) were based on the idea that patients with this 
pathology were “on the border” of psychosis (1). Historically, Stern used the term borderline to 
describe patients who showed neurotic and psychotic symptoms simultaneously (2). The current 
definition of BPD contains significant impairments in personality functioning and impairments in 
interpersonal functioning like empathy and intimacy. Pathological personality traits usually occur 
in the following domains: Negative Affectivity - characterized by emotional liability, anxiousness, 
separation insecurity, and depressivity; Disinhibition - characterized by impulsivity and risk taking;
Antagonism - characterized by hostility.
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According to the Diagnostic and Statistical Manual of Mental 
Disorders–Fifth Edition (DSM-5), psychotic symptoms such 
as auditory verbal hallucinations (AVH) and other “positive” 
symptoms of psychosis may be present in patients with BPD, but 
occur “only for brief periods in situations of distress” (3).
Recent studies suggest that, in patients with BPD, some 
hallucinations, like hearing voices, seem to be similar to those 
experienced by patients with psychotic disorders (4). Since 
the presence of attenuated psychotic symptoms is not unusual 
in BPD, it can be difficult to make the right diagnosis. The 
separation between the two diagnoses is even more difficult as 
there is some evidence that 10% of patients initially diagnosed 
with BPD actually do transition to a psychotic diagnosis (5).
Lifetime prevalence of schizophrenia is around 0.7% (6) and 
lifetime prevalence of BPD is mentioned to be four times higher 
at around 3% (7). While schizophrenia is often associated with 
a variety of concurrent psychiatric symptoms, initially, little 
attention was paid to the prevalence of comorbidity in patients at 
risk for schizophrenic psychosis (8).
At risk mental state (ARMS) is a term which is used by 
health professionals to describe adolescents and adults who are 
experiencing perceptual changes that may be early, low level, signs 
of psychosis (9). The at risk mental state term is actually used 
more commonly than the prodromal term because the prodromal 
term implies the inevitable onset of the illness rather than the 
fact that the course of the illness is variable (10). This means that 
“prodrome” is necessarily a retrospective concept (11).
Yung and colleagues (12) developed clinical criteria like the ultra-
high-risk (UHR) criteria to identify individuals at risk for psychosis. 
Specific assessment tools like Comprehensive Assessment of at Risk 
Mental State (CAARMS) (13) and Structured Interview for Prodromal 
Symptoms (SIPS) provide scores of symptom domains and they 
defined three states that lead to the three different UHR criteria (14):
 1. transient psychotic symptoms (brief limited psychotic 
symptoms, BLIPS)
2. attenuated psychotic symptoms (APS)
3. genetic risk combined with a functional decline
The presence of one of this three criteria is sufficient to fulfill 
the UHR state.
Another approach based on self-experienced subtle 
subclinical symptoms, the so called basic symptoms, was 
first described by Gerd Huber (15, 16). Basic symptoms are 
mainly subjectively experienced disturbances in motor action, 
perception, affect, thinking, speech, stress tolerance, and central 
vegetative functions (17). These concepts were mainly developed 
to detect the risk of psychosis as early as possible, ideally before 
functional impairments appear (18). They are thought to be the 
most immediate symptomatic expression of the neurobiological 
correlate of the psychotic illness (19). Basic symptoms are 
assessed with a structured manual (e.g., Schizophrenia Proneness 
Instrument, SPI-A) to enable a reliable detection and scoring of 
this symptoms (20).
Meanwhile, criteria from UHR are combined with the basic 
symptoms to increase the accuracy of prediction. The EPA 
guidance on early detection of clinical high-risk states currently 
recommends to use attenuated psychotic symptoms or COGDIS 
or BLIPS criteria alternatively (18).
Historically, our understanding of the early course of 
schizophrenia primarily has been limited to a retrospective 
assessment after the onset of the psychotic phase (8). During the 
last 20 years, research has focused on detecting psychosis in the 
prodromal stage by prospective studies. The average duration of 
the prodromal phase is 5 years (21), which should give the clinician 
enough time to begin with suitable interventions. Therefore, a 
number of studies focus on this prodromal phase in order to develop 
diagnostic and intervention strategies, for example:
PACE: Personal Assessment and Crisis Evaluation (22)
PRIME: Prevention through Risk Identification and 
Education (23)
EPOS: European Prediction of Psychosis Study (24)
NAPLS: North American Prodromal Longitudinal  
Study (25)
ZInEP: Zürcher Impulsprogramm zur nachhaltigen 
Entwicklung in der Psychiatrie (26)
PRONIA: Personalized Prognostic Tools for Early Psychosis 
Management (27)
On average 20% of the individuals who meet the basic symptom 
criteria make the transition to psychosis in the first year after 
presentation (28). Individuals who fit the UHR-Criteria were initially 
found to have rates of transition to psychosis of around 40% in the first 
12 months after presentation (29, 30). Fusar-Poli et al. (31) made a 
systematic review of at risk studies and found an average transition rate 
of 36% after three years. However, this transition rate has dropped to 
rates as low as 15% in recent studies. One explanation of the declined 
transition rate could lie in the increased awareness of attenuated 
psychotic symptoms, which consequently led to an earlier and more 
effective intervention to prevent the progression to psychosis (32). 
It has also been argued that the decline of transition rates could be 
explained by a treatment effect, for example with antipsychotics (33).
As the concept of at-risk mental states has gained extensive 
community awareness over the years, the so-called dilution effect 
has also been postulated. An increased attentiveness to at-risk 
mental state may have been associated with less selective referral 
patterns, in turn leading to a possible dilution of the pool of young 
people who are screened using the UHR criteria (33). This could 
explain the higher proportions of false-positive predictions in the 
more recent studies, which consequently may lead to stigma and 
unnecessary treatment (10).
A further problem of early detection of psychosis results from 
the lack of clear boundary between subthreshold and manifest 
psychotic symptoms. Meanwhile, there is much evidence for a 
continuum of psychosis from subclinical psychotic symptoms 
in general population (and conscripts) without indication for 
treatment up to manifest schizophrenia (34, 35). Moreover, 
persons with a subclinical disorder show rising and declining 
symptom states in the long-term course assessed with the 
Symptom-Checklist-90-R (36). Thus, depending on their symptom 
fluctuations, some persons might meet criteria for either at risk for 
psychosis or manifest schizophrenia over time. That means these 
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people show a dynamic course going back and forth across the 
diagnostic threshold of psychosis (37).
Another reason for a false-positive prediction could lie in 
the comorbidity in ultra-high-risk samples. Fusar-Poli et al. (38) 
showed in their study that comorbid depression and anxiety 
diagnoses had no effect on the risk of transition to psychosis. 
On the other hand, there is a prevalence of more than 40% for 
any personality disorder in several UHR samples (17). Mainly, 
the borderline personality disorder is common in UHR-Patients 
(5, 7). The association between BPD and the ultra-high-risk is 
unclear (39). Personality dimensions can be seen as vulnerability 
markers, which may increase the risk for psychosis in normal 
subjects (40). In a case control study from Thompson et al. 
(5), the presence of borderline personality feature was not 
associated with a reduced risk of transition to psychosis but 
they suggest that the types of attenuated psychotic symptoms 
might be different in UHR individuals with BPD compared 
with UHR-individuals without BPD features. What does this 
mean for the clinician? Is it important to screen patients with 
BPD for psychosis as well? We hypothesized that might be some 
individuals with borderline personality disorder which are falsely 
staged to the UHR state and that these individuals will not make 
the transition to psychosis. Additionally, we expected that there 
would be a significant correlation between borderline personality 
symptomatology and positive symptoms that predict the UHR 
state in our ZInEP sample. Furthermore, we wanted to investigate 
whether the types of attenuated psychotic symptoms are different 
in UHR individuals with BPS compared with UHR-individuals 
without BPS. Finally, we tried to figure out whether there is a 
correlation between borderline personality symptomatology and 
basic symptoms.
MATeRIAlS AND MeThODS
Sample
The sample contains 70 help-seeking individuals of the (ZInEP) 
early psychosis recognition center (26). These individuals 
were referred either by a general practitioner or psychiatrist to 
evaluate the risk of psychosis or they came by their own means 
after noticing certain symptoms and being afraid of developing 
a psychosis. All subjects were examined for both the presence of 
the UHR-state and the basic symptom criteria. The sample was 
then divided into individuals meeting the ultra-high-risk (UHR) 
criteria, the basic symptom (BS) criteria, or not meeting any of 
both criteria (for details and demographic data, see Results and 
Table 1). The borderline symptom checklist was assessed for all 
subjects in all three groups. Exclusion criteria were any substance 
addiction disorder, presence of a current, or past manifest 
psychotic disorder, any medical condition known to affect the 
brain or an estimated verbal IQ < 80. The study was approved 
by the local ethic committee and written informed consent was 
obtained before study enrolment.
Assessment
Basic symptoms were assessed by the schizophrenia proneness 
instrument (SPI-A). The SPI-A is a further development of the 
BSABS (Bonner Skala zur Beurteilung von Basissymptomen) 
based on a sample of retrospective prodromal patients. The 
scale consists of 40 items and six dimensions: affective-dynamic 
disturbances, cognitive-attentional impediments, cognitive 
disturbances, disturbances in experiencing the self and 
surroundings, body perception disturbances, and perception 
disturbances (20).
The basic symptom (BS) risk state for psychosis was defined 
by two basic symptom criteria:
 1. COPER-criterion: Presence of at least any one of the 
cognitive-perceptive basic symptoms with a SPI-A score 
of at least 3: thought interference, thought perseveration, 
thought pressure, thought blockages, disturbance of 
receptive speech, decreased ability to discriminate 
between ideas and perceptions, unstable ideas of reference, 
derealisation, visual perception disturbances, and acoustic 
perception disturbances.
2. COGDIS-criterion: Presence of at least any two of the 
following cognitive disturbances with a SPI-A score of at 
least 3: Inability to divide attention, thought interferences, 
thought pressure, thought blockages, disturbance of 
receptive speech, disturbances of expressive speech, 
unstable ideas of reference, disturbances of abstract 
thinking, and captivation of attention by details of the 
visual field.
COPER and COGDIS symptoms need to be present over the 
last 3 months and, for COPER, in addition, the first occurrence 
has to be more than 12 months ago.
TABle 1 | Demographic and clinical characteristics.
CN BS UhR Test statistics
n 10 34 26
Gender (F:M) 6:4 19:15 14:12 X2 = 0.112, p = 0,946
Age 22.2 ( ± 4.89) 23.59 ( ± 5.13) 19.88+-5.61 F = 3.43, p = 0,038
SIPS positive 3.4 (±-2.5) 4.15+-2.74 10.96+-3.55 F = 43.23, p < 0.001
SIPS negative 9.4+-4.6 9.76+-5.86 14.15+-6.82 F = 4.4, p = 0.016
SIPS global 5.3+-3.88 6.91+-3.39 9.39+-3.6 F = 6.09, p = 0.004
CPZe (Medication) 5.7+-18.02 9.12+-29.34 50.81+-91.87 F = 4.08, p = 0.021
BSL 23 16.1+-11.25 20.5+-15.14 36.42+-17.8 F = 9.73, p < 0.001
CN, criterion negative; BS, basic symptom; CPZe, antipsychotic medication status in chlorpromazine-equivalent dosage; UHR, ultra high risk (41).
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The UHR-state was assessed by the structured interview for 
prodromal symptoms (SIPS) (14):
1. APS: At least one attenuated psychotic symptom with a score 
between 3 and 5 in the SIPS score. The symptoms must have 
begun during the last 12 months or need to score at least one 
point higher than one year before. They need to occur with a 
mean frequency of at least once a week during the last months.
2. BLIPS (Brief limited psychotic symptoms): At least one 
symptom with the score 6 in the SIPS score. The symptoms 
must have started during the last 12 months and must occur 
at least a few minutes a day with a frequency of at least once a 
month. They need to regress without any intervention.
3. State-trait criteria: A first-degree relative with a history 
of psychosis or a schizotypal personality disorder plus a 
reduction of 30% in the General Assessment of Function 
Scale lead to the state-plus-trait criteria of UHR.
The borderline personality dimensions were assessed by the 
borderline symptom checklist (BSL-23). This is a short version 
from the BSL-95. The BSL items are based on criteria of the DSM 
4, the revised version of the Diagnostic Interview for BPD, and the 
opinion of clinical experts and BPD patients. The questionnaire uses 
a Likert-type rating format: 0 = not at all; 1 = a little; 2 = rather; 3 = 
much; and 4 = very strong. Data from an evaluation study suggest 
that the BSL-23 has good to excellent psychometric properties 
similar to the BSL-95, its ability to discriminate BPD patients 
from other psychiatric patients is high (42). The BSL is strongly 
associated with the presence of DSM 4 BPD symptoms assessed by 
a valid semistructured interview, although a cut-off score is missing 
(43). We defined a significant borderline symptomatology in scores 
at least one standard deviation higher than the mean score).
The medication of the subjects was assessed and 
chlorpromazine-equivalent dosages (CPZ) were calculated using 
the criteria of Andreasen et al. (41).
All subjects were followed up over three years as part of the 
ZInEP early recognition study (26, 44) to detect transitions in a 
manifest psychotic disorder.
Data Analyses
Statistical analyses were performed by Statistical Package for 
Social Science (SPSS) for windows version 24 (SPSS Inc. Chicago, 
IL, USA). Demographic and clinical characteristics between 
groups were compared by using Chi-squared and Fishers exact 
test for categorical variables or one-way ANOVA for continuous 
variables. To examine the influence of age and antipsychotic 
medication, both age and CPZ were included as covariate in the 
ANOVA. Kendall tau b correlations were used to calculate the 
association between BSL-23 and SIPS as well as SPI-A. Due to the 
strong overlap in the range of positive symptoms, we calculated 
correlations between the positives scores of the SIPS and the BSL.
ReSUlTS
Twenty-six (37%) individuals of the sample (N = 70) met Criteria 
for UHR (of these: 20 met only APS, three APS and BLIPS, two 
only BLIPS, and one met only genetic risk and functional decline). 
Thirty-four (48.5%) individuals exclusively (without UHR) 
met the basic symptom criteria (of these: 13 met only COPER 
and 21 COPER and COGDIS), while 10 (14.2%) met neither of 
those risk criteria (Table 1). Bonferroni post-hoc comparisons 
revealed that the UHR subjects had significant higher BSL mean 
scores than BS and CN (criterion negative) subjects. Within the 
BS group, there was no difference in BSL scores between COPER 
and COGDIS (see Figure 1).
No significant difference in BSL scores was found between 
subjects with transition into a manifest schizophrenic disorder 
(according to ICD-10) and subjects at risk for psychosis without 
transition. In addition, there was no significant difference with 
respect of attenuated psychotic symptoms (see Figure 2). There 
were also no statistical significant differences in BSL-scores in 
gender and age.
Since there was a significant difference in age and medication 
between the three groups, we performed a second ANOVA with 
age and CPZ (chlorpromazine-equivalent) (41) as a covariate. 
The second ANOVA also revealed a significant difference of the 
BSL score between the three groups (F = 6.78; p = 0.002). Post 
hoc: UHR versus BS p = 0.007 and UHR versus CN = 0.008). 
However, the SIPS negative score did no longer differ significantly 
between the three groups when age and CPZ used as a covariate.
In the correlation analysis of positive symptoms, we 
found a significant correlation between the BSL score and 
the following three SIPS positive items: “unusual thought 
content,” “suspiciousness/persecutory ideas,” and “perceptual 
abnormalities/hallucinations.” The correlation between the 
BSL score and the other two SIPS Items “grandiosity” and 
“disorganized communication” were not statistically significant 
(Table 2).
Furthermore, there was no significant correlation between 
basic symptoms which define the high risk state and the BSL 
score (Supplement Table S1).
In our sample of 70 patients, 60 were rated as at risk mental 
state. Six of these individuals transitioned to psychosis leading 
to a transition rate of 10%. As a cutoff score of the BSL does not 
exist, we defined a significant borderline symptomatology in 
the range of one standard deviation above the mean score. In 
our sample, this was a score higher than 42 on the BSL. Based 
on this definition, 11 subjects in our sample had a pronounced 
and relevant borderline symptomatology. Only one of these 
11 subjects made a transition to manifest schizophrenia; thus, 
the transition rate is 9.1%. The group with low borderline 
symptomatology (BSL-scores below 42) contained 49 individuals 
and 5 transitions, leading to a transition rate of 10.2%. Hence, the 
transition rates are almost equal.
DISCUSSION
Transient hallucinations are a common symptom in BPD as 
well as a common attenuated positive symptom, which is part 
of the UHR state. Therefore, in patients with a BDP, it is difficult 
to determinate whether transient hallucinations are a symptom 
of the BPD alone or if they in fact pose as a risk factor for a 
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transition to psychosis. As we see in the significant correlation 
between BSL-scores and some important “prodromal” positive 
symptoms of schizophrenia (like unusual thought content, 
suspiciousness and hallucinations) in the SIPS score, it is difficult 
to determine whether the symptoms are part of a at risk mental 
state or the borderline personality. Thus, longitudinal studies 
with several follow up examinations are needed. If the score of 
the hallucinations turns out to stay equal, the hallucinations may 
possibly be part of the borderline personality symptomatology 
alone. If on the other hand the score increases, this may predict a 
transition to psychosis. Patients with borderline symptoms should 
also be screened and treated for the risk of developing a psychotic 
disorder if they present attenuated psychotic symptoms or basic 
symptoms that meet an ultra high risk or basic symptom risk 
state. As we found no statistical significant correlation between 
the BSL-score and the basic symptom risk states COPER and 
COGDIS, any patient with BPD who presents basic symptoms 
meeting the high-risk state should be observed and treated 
concerning the risk of making a transition to psychosis.
The fact that we found almost equal transition rates in the 
group with low borderline personality symptomatology (10.2%) 
and high borderline personality symptomatology (9.1%) is a 
FIgURe 1 | Borderline symptom list (BSL) score separated according to the presence of basic symptom criteria COPER and COGDIS.
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contradiction to our suggestion, that UHR individuals with 
high BSL-scores (more than one standard deviation to the mean 
score) show lower rates of transition to psychosis. Concerning 
these results, we have to keep the limitations of the study in 
mind. First of all, it is a small sample (70 individuals) with 
only six transitions, in which we only have one transition in 
the group with high borderline personality symptomatology. 
Further studies with a larger number of cases are needed in order 
FIgURe 2 | Borderline symptom list (BSL) score separated according transition into manifest psychosis and according to the presence of the attenuated positive 
symptom (APS) criterion.
TABle 2 | Correlation (Kendall tau b) between borderline symptom checklist (BSL 23) and Structured Interview for Prodromal Symptoms (SIPS) positive items.
SIPS P1 Unusual 
Thought content
SIPS P2 
Suspiciousness/
persecutory ideas
SIPS P3 grandiosity SIPS P4 hallucinations SIPS P5 Disorganized 
communication
BSL 23 r = 0.202 p = 0.024 r = 0.201 p = 0.026 r = 0.128 p = 0.181 r = 0.228 p = 0.012 r = 0.088 p = 0.346
Significant p-values in bold.
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to clarify the correlation between borderline symptomatology 
and risk for psychosis. In addition, future investigations should 
investigate the comorbidity of psychotic symptoms in other 
cluster A and B personality disorders too. Another limitation is 
the self- rating Instrument BSL 23 with missing cut off scores, 
so that we could not define the state of a significant borderline 
symptomatology exactly. All in all, these results show that it is 
very important to focus on individuals with symptoms of BPD as 
well when researching a UHR cohort.
As we suggested, some of the APS items like unusual thought 
content, suspiciousness/persecutory ideas, and perceptual 
abnormalities/hallucinations that lead to the UHR state have a 
strong correlation to the BSL-scores. These are in general the 
psychotic symptoms which are seen clinically often in borderline 
personality disorder. Psychotic symptoms in patients with 
borderline personality disorder usually occur for brief periods 
of time in stressful situations. Severe difficulties in interpersonal 
functioning can induce the development of undue suspiciousness, 
ideas of reference, and other symptoms of nondelusinal paranoia 
(45). The UHR state is characterized by brief psychotic or 
attenuated psychotic symptoms (BLIPS and APS) which might 
be induced by stress. Moreover, hallucinations, especially 
auditory verbal hallucinations, are a common symptom in 
borderline personality disorder (46). The two SIPS items that 
did not correlate with the BSL (grandiosity and disorganized 
communication) are usually not seen in BPD.
Furthermore, we should keep the existing comorbidity of BPD 
and schizophrenia in mind. There are only a few studies that have 
examined BPD in individuals with schizophrenia and the results 
differ considerably ranging between 3% and 25% (47). BPD 
seems to occur more often in UHR and first episode patients. 
This means that up to a quarter of first episode patients could 
suffer from this comorbidity (48). In the study from Bahorik 
and Eack (47), patients with schizophrenia and BPD improved 
less in overall psychiatric symptomatology, had poorer global 
functioning, and were rehospitalized at significantly higher rates 
than patients with schizophrenia alone. As this comorbidity 
often leads to severe illness and difficulties in compliance, it is 
necessary to recognize this risk as early as possible in order to 
provide an adequate treatment.
We conclude that the diagnosis of borderline personality 
disorder should not be an exclusion criterion for the screening for 
psychosis or for an early intervention treatment. In particular, the 
basic symptoms appear to be completely independent of comorbid 
borderline symptoms. On the other hand, not every patient with 
BPD (especially those not suffering from hallucinations, unusual 
thought content or persecutory ideas) should automatically be 
screened for the risk of developing a psychotic disorder.
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